Cargando…
Neoadjuvant immunotherapy in breast cancer: a paradigm shift?
Despite advances in clinical management, a proportion of patients with early-stage triple-negative breast cancer (TNBC) recur after local treatment. The concept of neoadjuvant systemic therapy has been widely adopted to improve clinical outcomes of patients with TNBC and other breast tumour types. R...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864681/ https://www.ncbi.nlm.nih.gov/pubmed/33574892 http://dx.doi.org/10.3332/ecancer.2020.1147 |